Navigation Links
Juventas Therapeutics Demonstrates JVS-100 Delivery to Patients with Heart Failure is Safe and Provides Clinical Benefit
Date:5/24/2011

CLEVELAND, May 24, 2011 /PRNewswire/ -- Juventas Therapeutics is a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease.  The Company's lead product, JVS-100, encodes Stromal cell-Derived Factor 1 (SDF-1) which has been shown to repair damaged tissue through recruitment of circulating stem cells to the site of injury, prevention of ongoing cell death and restoration of blood flow.  Juventas recently presented the results from its Phase I heart failure trial at the 14th Annual Meeting of the American Society of Gene and Cell Therapy.

The 17-person, open-label, dose-escalation study targeted New York Heart Association (NYHA) class III heart failure patients. Class III patients represent approximately a quarter of the 6 million heart failure patients in the United States and account for half of all heart failure hospital admissions.

"We wanted to target truly sick patients for whom there are currently no real therapeutic options," states Marc Penn, M.D., Ph.D., scientific founder and Chief Medical Officer for Juventas.  "These patients tend to have a rapidly deteriorating quality of life and the potential to provide clinical benefit is meaningful."

The clinical trial met its safety endpoints and JVS-100 was well-tolerated by all patients at all doses tested.  At four months post-treatment, patients in the targeted therapeutic dose range, are showing clinically-relevant and statistically-significant median improvements of 36 meters for 6 minute walk distance (6MWD) and 22 points in the Minnesota Living with Heart Failure Questionnaire (MLHFQ).  Nearly half of the patients improved a full NYHA heart class and, importantly, no patients worsened in heart class. Echocardiographs demonstrated that the patients' cardiac function stabilized with dose-dependent trends toward improvement in left ventricular end systolic volume (LVESV) and left ventricular ej
'/>"/>

SOURCE Juventas Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Juventas Therapeutics Initiating Phase II Clinical Trial of JVS-100 for Treatment of Critical Limb Ischemia
2. Northwest Biotherapeutics to Present at American Society of Cell and Gene Therapy
3. Northwest Biotherapeutics and the Fraunhofer Institute for Cell Therapy and Immunology are Partnering for Clinical Trials and Compassionate Use Cases in Europe
4. Nile Therapeutics to Transition to OTCQB Marketplace
5. Halozyme Therapeutics Reports First Quarter 2011 Financial Results
6. InVivo Therapeutics and The Miami Project to Cure Paralysis Form Strategic Research Collaboration to Develop Novel Treatments for Spinal Cord Injuries
7. Talecris Biotherapeutics Announces Results of Annual Stockholders Meeting
8. Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology
9. Cell Therapeutics Retires 7.5% Convertible Senior Notes
10. Talecris Biotherapeutics Announces First Quarter 2011 Results
11. Nektar Therapeutics Reports First Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... NEW YORK , Dec. 24, 2014 ... biopharmaceutical company advancing patient care in critical areas, announced ... shares of common stock, and warrants to purchase up ... an offering price of $4.00 per share and $.01 ... price of $5.00, are exercisable immediately, and expire 5 ...
(Date:12/24/2014)... “Preparative & Process Chromatography Market by Instrument (Liquid ... Valves, Guages, Seals), Accessories, Services, End User (Biotechnology, ... provides a detailed overview of the major drivers, ... impacting the preparative and process chromatography market along ... and share analysis. , Full Copy of ...
(Date:12/24/2014)... SoundConnect’s 2015 ... introduce cutting edge communication technology, provide continued ... platform upgrades. This webinar series demonstrates online ... their quest to leverage web conferencing’s most ... SoundConnect’s Marketing Manager, Seanna Baumgartner, “Our webinars ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 ... mercaptan such as its definition, classification, application ... product specification, manufacturing process, and product cost ... and applications. The analysis also covers upstream ... channels, industry development trend and proposals. In ...
Breaking Biology Technology:PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... ROCKVILLE, Md., Nov. 26 Human Genome,Sciences, Inc. (Nasdaq: ... the,Piper Jaffray 19th Annual Health Care Conference will be ... (Logo: http://www.newscom.com/cgi-bin/prnh/20010612/HGSLOGO ), A member of ... of the company on Wednesday, November 28, 2007 at ...
... Genta,Incorporated (Nasdaq: GNTA ) announced today ... Raymond P. Warrell, Jr., will provide a,company overview ... Capital,Markets 4th Annual Healthcare Conference. Genta,s presentation is ... at the New York Palace Hotel,New York, NY., ...
... Orthopedic Surgeons and Rheumatologists Performing More Procedures, ... US,Hyaluronic Acid (HA) Viscosupplementation Marketrack(TM) service, which,captures data ... groups provided more HA knee injections in Q3 ... in both groups, there are substantial,differences in the ...
Cached Biology Technology:Genta Incorporated to Present at Lazard Capital Markets 4th Annual Healthcare Conference 2Genta Incorporated to Present at Lazard Capital Markets 4th Annual Healthcare Conference 3Hyaluronic Acid Knee Procedures Grow 38% from Q3 2006 to Q3 2007 2
(Date:12/5/2014)... -- Tute Genomics, a leader in cloud-based solutions for genome ... led by UK-based Eurovestech. Peak Ventures and a number ... "We are at a pivotal time in ... seeks new approaches for the diagnosis, treatment and prevention ... and CEO of Tute Genomics. "One of the main ...
(Date:12/3/2014)... Calif. , Dec. 2, 2014   ... globally deployed, innovative test solutions for military, aerospace, ... newest version of its successful TS-900 PXI ... performance and features of high-end systems to customers ... outstanding value compared to traditional ATE. ...
(Date:11/21/2014)... According to a new market ... RFID, Access Control, Intrusion Detection, Parking Management, Under Vehicle ... Service Geography - Global Forecasts to 2020", published by ... be around $25 Billion in 2014 and is expected ... CAGR of 8.69%. Browse 116 market data ...
Breaking Biology News(10 mins):Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
... Lithosphere is now online. Locations studied include the ... Wet Mountains of Central Colorado, USA; the Basgo ... Utah, USA; Knight Inlet in the southwestern Coast ... shear zones in the western Canadian Shield of ...
... Genetic tests can now tell us whether we are ... asthma and a number of other conditions., Other genetic tests ... be harmed by side effects linked to your genetic code. ... illnesses in others will require that doctors have access to ...
... The forage grasses and other plants beef cattle ... University animal science researchers report that steers grazing on one ... growth, carcass and meat quality. The research can help ... are looking to add weight and value to their animals ...
Cached Biology News:Lithosphere interprets earth 2Lithosphere interprets earth 3Lithosphere interprets earth 4Lithosphere interprets earth 5Lithosphere interprets earth 6Lithosphere interprets earth 7Genetics in Medicine publishes special issue dedicated to genomics in electronic health records 2Genetics in Medicine publishes special issue dedicated to genomics in electronic health records 3Genetics in Medicine publishes special issue dedicated to genomics in electronic health records 4
Plasmid expressing the LacZ reporter gene....
Human SEAP ORF, provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
... These 2800mL PYREX Fernbach-style culture flasks ... of the flask bottom to achieve maximal ... have a large marking spot., A wide ... these bottles including:, Polypropylene colored caps ...
... of purified RNA samples., , This product ... aqueous RNA samples that have been pre-purified ... silica, oligo dT etc or other kits. ... necessary components for the stabilization of nanogram ...
Biology Products: